Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Trial of BI-1206 + Rituximab +/- Acalabrutinib in Relapsed/Refractory Indolent B-Cell NHL
NCT03571568Phase 2Recruiting
- Sponsor
- BioInvent International
- Start
- May 2018
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of BI-1206 in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by BioInvent International. Primary endpoints: Adverse Events and Serious Adverse Events at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started May 2018; status: recruiting.
02
Drugs
BI-1206
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03571568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571568.